---
title: 'Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to
  Treatment'
date: '2024-01-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38184096/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240107170847&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: Patients with type 1 AIP and elevated IgG4 level may need
  closer monitoring. For remission induction, a starting dose of 0.4 mg/kg/day for
  2 weeks followed by a short taper period seems effective. This study provides no
  evidence to support more aggressive ...'
disable_comments: true
---
CONCLUSION: Patients with type 1 AIP and elevated IgG4 level may need closer monitoring. For remission induction, a starting dose of 0.4 mg/kg/day for 2 weeks followed by a short taper period seems effective. This study provides no evidence to support more aggressive ...